These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 1638557)
21. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Ye JN; Cheung NK Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513 [TBL] [Abstract][Full Text] [Related]
22. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876 [TBL] [Abstract][Full Text] [Related]
23. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
24. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. Siebert N; Eger C; Seidel D; Jüttner M; Lode HN J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144 [TBL] [Abstract][Full Text] [Related]
26. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131 [TBL] [Abstract][Full Text] [Related]
27. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592 [TBL] [Abstract][Full Text] [Related]
28. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Castel V; Segura V; Cañete A Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409 [TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
30. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. Kushner BH; Kramer K; Modak S; Cheung NK J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563 [TBL] [Abstract][Full Text] [Related]
31. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735 [TBL] [Abstract][Full Text] [Related]
32. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079 [TBL] [Abstract][Full Text] [Related]
33. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881 [TBL] [Abstract][Full Text] [Related]
34. Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. Cheung IY; Mauguen A; Modak S; Ragupathi G; Basu EM; Roberts SS; Kushner BH; Cheung NK JAMA Oncol; 2023 Feb; 9(2):242-250. PubMed ID: 36547975 [TBL] [Abstract][Full Text] [Related]
35. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma--a report of a series. Wallace MS; Lee J; Sorkin L; Dunn JS; Yaksh T; Yu A Anesth Analg; 1997 Oct; 85(4):794-6. PubMed ID: 9322457 [No Abstract] [Full Text] [Related]
36. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Sondel PM; Hank JA Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407 [TBL] [Abstract][Full Text] [Related]
37. Disialoganglioside directed immunotherapy of neuroblastoma. Modak S; Cheung NK Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560 [TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. Kawashima I; Tada N; Fujimori T; Tai T J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721 [TBL] [Abstract][Full Text] [Related]
39. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976 [TBL] [Abstract][Full Text] [Related]
40. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. Cheung NK; Von Hoff DD; Strandjord SE; Coccia PF J Clin Oncol; 1986 Mar; 4(3):363-9. PubMed ID: 3081691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]